Sanofi and Orano Med partner on next-gen radioligand therapies

Sanofi (Euronext: SAN) has entered into an agreement with Orano Med, a subsidiary of the Orano Group (Euronext: AREB), to advance the development of radioligand therapies for rare cancers.

The companies will pool their expertise in oncology and nuclear technology, aiming to improve outcomes for patients with difficult-to-treat cancers.

This will involve harnessing the precision-targeting ability of radioligand therapies, combined with the cell-killing power of alpha-emitting isotopes, to target cancer while minimizing damage to healthy tissues.